Jefferies Group set a $122.00 price target on AbbVie (NYSE:ABBV) in a report issued on Friday. The brokerage currently has a buy rating on the stock. Jefferies Group also issued estimates for AbbVie’s FY2018 earnings at $7.52 EPS and FY2019 earnings at $8.97 EPS.

Several other equities analysts have also weighed in on the company. Credit Suisse Group set a $109.00 price objective on AbbVie and gave the company a hold rating in a report on Tuesday, April 10th. Barclays cut their price target on AbbVie from $120.00 to $102.00 and set an equal weight rating for the company in a report on Thursday, April 5th. BMO Capital Markets reaffirmed a sell rating and issued a $80.00 price target on shares of AbbVie in a report on Thursday, April 5th. ValuEngine lowered AbbVie from a strong-buy rating to a buy rating in a report on Wednesday, March 28th. Finally, Bank of America set a $120.00 price target on AbbVie and gave the stock a hold rating in a report on Monday, March 26th. One analyst has rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $117.85.

How to Become a New Pot Stock Millionaire

Shares of ABBV opened at $92.60 on Friday. The company has a debt-to-equity ratio of 6.07, a current ratio of 1.28 and a quick ratio of 1.18. The company has a market cap of $145,823.56, a P/E ratio of 16.54, a price-to-earnings-growth ratio of 0.87 and a beta of 1.61. AbbVie has a 12 month low of $63.12 and a 12 month high of $125.86.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, beating the Zacks’ consensus estimate of $1.44 by $0.04. AbbVie had a return on equity of 158.15% and a net margin of 18.82%. The company had revenue of $7.74 billion during the quarter, compared to the consensus estimate of $7.53 billion. During the same period last year, the business posted $1.20 earnings per share. AbbVie’s revenue was up 13.9% on a year-over-year basis. equities research analysts predict that AbbVie will post 7.53 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be paid a dividend of $0.96 per share. This is a positive change from AbbVie’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $3.84 annualized dividend and a yield of 4.15%. AbbVie’s dividend payout ratio (DPR) is currently 68.57%.

AbbVie announced that its board has initiated a stock buyback plan on Thursday, February 15th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.

In related news, VP Robert A. Michael sold 992 shares of AbbVie stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $120.31, for a total transaction of $119,347.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Carlos Alban sold 83,574 shares of AbbVie stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $114.49, for a total value of $9,568,387.26. Following the sale, the executive vice president now directly owns 133,026 shares of the company’s stock, valued at approximately $15,230,146.74. The disclosure for this sale can be found here. Insiders have sold 211,197 shares of company stock valued at $24,585,575 in the last three months. 0.07% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of ABBV. Los Angeles Capital Management & Equity Research Inc. raised its position in AbbVie by 24.5% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 740,392 shares of the company’s stock valued at $53,686,000 after purchasing an additional 145,691 shares in the last quarter. Spectrum Management Group Inc. raised its position in AbbVie by 11.5% during the second quarter. Spectrum Management Group Inc. now owns 28,100 shares of the company’s stock valued at $2,038,000 after purchasing an additional 2,892 shares in the last quarter. AGF Investments America Inc. raised its position in AbbVie by 3.6% during the second quarter. AGF Investments America Inc. now owns 29,064 shares of the company’s stock valued at $2,107,000 after purchasing an additional 1,017 shares in the last quarter. Ffcm LLC raised its position in AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares in the last quarter. Finally, Fiduciary Trust Co. raised its position in AbbVie by 3.2% during the second quarter. Fiduciary Trust Co. now owns 321,953 shares of the company’s stock valued at $23,345,000 after purchasing an additional 10,113 shares in the last quarter. 70.57% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Jefferies Group Analysts Give AbbVie (ABBV) a $122.00 Price Target” was posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/04/16/jefferies-group-analysts-give-abbvie-abbv-a-122-00-price-target.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.